NASDAQ: NVCTNuvectis Pharma Inc Stock
$6.71+0.07 (+1.05%)
Updated Oct 31, 2025
NVCT Price
$6.71
Fair Value Price
$1.08
Market Cap
$170.82M
52 Week Low
$4.44
52 Week High
$11.80
P/E
-5.74x
P/B
10.12x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$22.07M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.6
Operating Cash Flow
-$12M
Beta
0.37
Next Earnings
Nov 11, 2025
Ex-Dividend
N/A
Next Dividend
N/A
NVCT Overview
Nuvectis Pharma, Inc. is developing precision treatments for unmet medical needs in oncology. It is using target selection, drug profiling, and clinical and regulatory execution to build a pipeline of anticancer targeted-therapy drugs. The company's lead product candidate, NXP800, targets ovarian clear cell carcinoma (OCCC) and endometrioid ovarian cancer. Nuvectis was incorporated in 2020 and is headquartered in Fort Lee, NJ.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NVCT's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NVCT
Ranked#395 of 488
Ranked#395 of 488
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.65 | A | |
| $93.48 | A | |
| $14.66 | A |
Be the first to know about important NVCT news, forecast changes, insider trades & much more!
NVCT News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NVCT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NVCT ($6.71) is overvalued by 519.59% relative to our estimate of its Fair Value price of $1.08 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NVCT ($6.71) is not significantly undervalued (519.59%) relative to our estimate of its Fair Value price of $1.08 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NVCT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NVCT due diligence checks available for Premium users.
Valuation
NVCT fair value
Fair Value of NVCT stock based on Discounted Cash Flow (DCF)
Price
$6.71
Fair Value
$1.08
Overvalued by
519.59%
NVCT ($6.71) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NVCT ($6.71) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NVCT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NVCT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.74x
Industry
-9.17x
Market
41.65x
NVCT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.12x
Industry
4.99x
NVCT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NVCT's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.3M
Profit Margin
0%
NVCT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$27.0M
Liabilities
$10.1M
Debt to equity
0.6
NVCT's short-term assets ($27.01M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NVCT's short-term assets ($27.01M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NVCT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.4M
Investing
$0.0
Financing
$296.0k
NVCT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NVCT vs Biotech Stocks
Nuvectis Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.